Merck is racing to be first on the market among contenders in the PD-1 field of cancer therapy, and the European Medicines Agency has agreed to review its pembrolizumab as a treatment for advanced melanoma.
European regulators are recommending approval for Bristol-Myers Squibb's daclatasvir, an hepatitis C-fighting antiviral that plays a key role in the company's planned combo treatment.
Welcome to the latest edition of our weekly EuroBiotech Report. We lead this week on news that Neil Woodford's much-discussed fund is starting to take shape, with a $50 million (€36.8 million) investment in Elan-spinoff Prothena among its first batch of positions. And more.
Cataracts are big business for Abbott. It's ready to roll out the latest in its line of implantable Tecnis lenses in Europe after recently receiving a CE Mark for the product, which will be used to treat cataract patients who may also have a diminished ability, due to aging, to focus on near objects (presbyopia).
At the Live Interventional Neuroradiology & Neurosurgery Course in, Paris Philips Healthcare launched a new device for minimally invasive image guided neurological surgeries, such as ischemic stroke or large neck aneurism, the NeuroSuite.
In 2012, an immediate action plan as well as new medical device legislation were proposed in the European Union. This week, the Employment, Social Policy, Health and Consumer Affairs Council of the European Commission declared the action plan a success and issued its vision for upcoming legislative changes.
In this week's EuroBiotech report, the European Investment Bank is using some of its €24 billion ($33 billion) fund to back drug development, Parisian biotech Cellectis is setting up shop in the U.S. after striking a deal worth up to $2.8 billion with Pfizer, and more.
Earlier this year, Indian generic drugmaker Lupin picked up a Netherlands-based manufacturing specialist to extend its reach in sterile injectable drugs within Europe. The company, however, is not done buying capacity and capabilities throughout the continent.
British regenerative-medicine company Tissue Regenix told Bloomberg that it is an attractive acquisition target given its tax and structural advantages. The small cap recently launched its DermaPure decellularized dermis product in the U.S.
In this week's edition of the EuroBiotech Report, the European Commission is investigating the United Kingdom's patent box--which partly motivated Pfizer's pursuit of AstraZeneca--and other tax laws in the region. And more.